OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
Open Access
Abstract
Background: Pharmacological targeting aberrant activation of epidermal growth factor receptor tyrosine kinase signaling is an established approach to treating lung adenocarcinoma. Osimertinib is a tyrosine kinase approved and effective in treating lung adenocarcinomas that have one of several common activating mutations in epidermal growth factor receptor. The emergence of resistance to osimertinib after a year or two is the rule. We developed a five-drug adjuvant regimen designed to increase osimertinib’s growth inhibition and thereby delay the development of resistance. Areas of Uncertainty: Although the assembled preclinical data is strong, preclinical data and the following clinical trial results can be discrepant. The safety of OPALS drugs when used individually is excellent. We have no data from humans on their tolerability when used as an ensemble. That there is no data from the individual drugs to suspect problematic interaction does not exclude the possibility. Data Sources: All relevant PubMed.org articles on the OPALS drugs and corresponding pathophysiology of lung adenocarcinoma and glioblastoma were reviewed. Therapeutic Opinion: The five drugs of OPALS are in wide use in general medicine for non-oncology indications. OPALS uses the anti-protozoal drug pyrimethamine, the antihistamine cyproheptadine, the antibiotic azithromycin, the antihistamine loratadine, and the potassium sparing diuretic spironolactone. We show how these inexpensive and generically available drugs intersect with and inhibit lung adenocarcinoma growth drive. We also review data showing that both OPALS adjuvant drugs and osimertinib have data showing they may be active in suppressing glioblastoma growth.Keywords
This publication has 117 references indexed in Scilit:
- Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cellsInternational Journal of Oncology, 2013
- Mast cells and histamine enhance the proliferation of non-small cell lung cancer cellsLung Cancer, 2012
- Mineralocorticoid and Epidermal Growth Factor ReceptorsHypertension, 2011
- Profound blocking cxcr4 signaling at multiple points using synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct.Turkish Neurosurgery, 2010
- Nongenotropic aldosterone effects and the EGFR: Interaction and biological relevanceSteroids, 2008
- Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/EGFR trans-activation pathway in the M1 kidney CCD cell lineThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramineFEBS Letters, 2004
- High and prolonged pulmonary tissue concentrations of azithromycin following a single oral doseEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndromeCancer, 1991
- Mechanism of the antimineralocorticoid effects of spirolactonesKidney International, 1981